zonisamide has been researched along with Bipolar Disorder in 21 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Weight gain is commonly observed with olanzapine treatment." | 9.16 | A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. ( Guerdjikova, AI; Keck, PE; Martens, B; McCoy, J; McElroy, SL; Moeller, D; Mori, N; Winstanley, E, 2012) |
| "One hundred four patients with Bipolar Disorder, Type I, II or NOS, in a manic, hypomanic or mixed state of illness were randomized to either adjunctive zonisamide or placebo." | 9.15 | Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. ( Dauphinais, D; Knable, M; Polanski, M; Rosenthal, J; Rosenthal, N, 2011) |
| "To assess the effectiveness and safety of zonisamide in bipolar disorder." | 9.13 | Is adjunctive open-label zonisamide effective for bipolar disorder? ( Berv, DA; Filkowski, MM; Ghaemi, SN; Klugman, J; Pardo, TB; Shirzadi, AA, 2008) |
| "Adjunctive zonisamide was associated with beneficial effects on mood and body weight in some patients with bipolar disorders, but was also associated with a high discontinuation rate due to worsening mood symptoms." | 9.11 | Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. ( Altshuler, LL; Black, D; Frye, MA; Grunze, H; Keck, PE; Kupka, RW; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| " Open reports suggest usefulness of gabapentin as an adjunct in bipolar disorder, but double-blind trials failed to confirm efficacy in acute mania and treatment-resistant rapid-cycling bipolar disorder." | 6.20 | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. ( Calabrese, JR; Kroeker, G; Kusumakar, V; Rao, R; Scarrow, G; Yatham, LN, 2002) |
| "Weight gain is commonly observed with olanzapine treatment." | 5.16 | A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. ( Guerdjikova, AI; Keck, PE; Martens, B; McCoy, J; McElroy, SL; Moeller, D; Mori, N; Winstanley, E, 2012) |
| "One hundred four patients with Bipolar Disorder, Type I, II or NOS, in a manic, hypomanic or mixed state of illness were randomized to either adjunctive zonisamide or placebo." | 5.15 | Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. ( Dauphinais, D; Knable, M; Polanski, M; Rosenthal, J; Rosenthal, N, 2011) |
| "To assess the effectiveness and safety of zonisamide in bipolar disorder." | 5.13 | Is adjunctive open-label zonisamide effective for bipolar disorder? ( Berv, DA; Filkowski, MM; Ghaemi, SN; Klugman, J; Pardo, TB; Shirzadi, AA, 2008) |
| "Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study." | 5.11 | A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. ( Anand, A; Bukhari, L; Jennings, SA; Kamat, M; Lee, C; Lightfoot, J; Nurnberger, JI; Shekhar, A, 2005) |
| "Adjunctive zonisamide was associated with beneficial effects on mood and body weight in some patients with bipolar disorders, but was also associated with a high discontinuation rate due to worsening mood symptoms." | 5.11 | Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. ( Altshuler, LL; Black, D; Frye, MA; Grunze, H; Keck, PE; Kupka, RW; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| "On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe." | 4.85 | [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009) |
| "Zonisamide has been proven to have a pharmacological profile that is very similar to that of carbamazepine." | 2.67 | The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. ( Arata, E; Kamijima, K; Kanba, S; Kinoshita, N; Koshikawa, H; Nibuya, M; Otaki, J; Suzuki, T; Tajima, O; Yagi, G, 1994) |
| "Zonisamide was found to have a very low switch rate and modest effectiveness." | 2.44 | Zonisamide for bipolar depression. ( Findling, RL; Wilson, MS, 2007) |
| "Eating disorders are commonly associated with depressive symptoms." | 1.35 | Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series. ( Lee, EL; Tor, PC, 2008) |
| " Patients received a mean (+/- SD) zonisamide dosage of 236 (+/- 68) mg/day." | 1.32 | Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. ( Baldassano, CF; Chang, A; Ghaemi, SN; Lipari, M; Lyman, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 17 (80.95) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tor, PC | 1 |
| Lee, EL | 1 |
| Janszky, J | 1 |
| McElroy, SL | 3 |
| Winstanley, E | 1 |
| Mori, N | 1 |
| Martens, B | 1 |
| McCoy, J | 1 |
| Moeller, D | 1 |
| Guerdjikova, AI | 1 |
| Keck, PE | 3 |
| Dauphinais, D | 1 |
| Knable, M | 1 |
| Rosenthal, J | 1 |
| Polanski, M | 1 |
| Rosenthal, N | 1 |
| Berigan, TR | 1 |
| Shelton, RC | 1 |
| Ozawa, K | 1 |
| Kobayashi, K | 1 |
| Noda, S | 1 |
| Iyo, M | 1 |
| Yatham, LN | 2 |
| Baldassano, CF | 2 |
| Ghaemi, SN | 3 |
| Chang, A | 1 |
| Lyman, A | 1 |
| Lipari, M | 1 |
| Majeres, KD | 1 |
| Suppes, T | 2 |
| Anand, A | 1 |
| Bukhari, L | 1 |
| Jennings, SA | 1 |
| Lee, C | 1 |
| Kamat, M | 1 |
| Shekhar, A | 1 |
| Nurnberger, JI | 1 |
| Lightfoot, J | 1 |
| Black, D | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Nolen, WA | 1 |
| Kupka, RW | 1 |
| Leverich, GS | 1 |
| Walden, J | 1 |
| Grunze, H | 1 |
| Post, RM | 1 |
| Howland, RH | 1 |
| Zablotsky, B | 1 |
| Filkowski, MM | 2 |
| Dunn, RT | 1 |
| Pardo, TB | 2 |
| Isenstein, E | 1 |
| Sullivan, KL | 1 |
| Ward, CL | 1 |
| Zesiewicz, TA | 1 |
| Kotwal, R | 1 |
| Wilson, MS | 1 |
| Findling, RL | 1 |
| Shirzadi, AA | 1 |
| Klugman, J | 1 |
| Berv, DA | 1 |
| Kanba, S | 1 |
| Yagi, G | 1 |
| Kamijima, K | 1 |
| Suzuki, T | 1 |
| Tajima, O | 1 |
| Otaki, J | 1 |
| Arata, E | 1 |
| Koshikawa, H | 1 |
| Nibuya, M | 1 |
| Kinoshita, N | 1 |
| Kusumakar, V | 1 |
| Calabrese, JR | 1 |
| Rao, R | 1 |
| Scarrow, G | 1 |
| Kroeker, G | 1 |
| Charles, CL | 1 |
| Stoesz, L | 1 |
| Tollefson, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain[NCT00363376] | Phase 3 | 42 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
7 reviews available for zonisamide and Bipolar Disorder
| Article | Year |
|---|---|
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy | 2009 |
Treating bipolar depression.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2003 |
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
Comorbidity of eating disorders with bipolar disorder and treatment implications.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Disruptive, Impulse Cont | 2006 |
Zonisamide for bipolar depression.
Topics: Bipolar Disorder; Humans; Isoxazoles; Pilot Projects; Zonisamide | 2007 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
8 trials available for zonisamide and Bipolar Disorder
| Article | Year |
|---|---|
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cognition Disorders | 2012 |
Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cyclothymic Disorder; Double-Blind Method; Drug Admin | 2011 |
A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; F | 2005 |
Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.
Topics: Adult; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Body Mass Index; Body Weight; Drug Therap | 2005 |
An open prospective study of zonisamide in acute bipolar depression.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Depressive Disorder; Female; Humans; Isoxaz | 2006 |
Is adjunctive open-label zonisamide effective for bipolar disorder?
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical M | 2008 |
The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Female; Humans; Isoxazoles; Male; Middle Aged; Psych | 1994 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
7 other studies available for zonisamide and Bipolar Disorder
| Article | Year |
|---|---|
Treatment emergent mania responding to valproate in a Chinese female adolescent population with eating disorders: a case series.
Topics: Adolescent; Anorexia Nervosa; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bulimia Nervosa; | 2008 |
Zonisamide treatment of bipolar disorder: a case report.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Humans; Isoxazoles; Male; Middle Aged; Zonisamide | 2002 |
Zonisamide-induced depression and mania in patients with epilepsy.
Topics: Adult; Bipolar Disorder; Depression; Epilepsy; Humans; Isoxazoles; Male; Polypharmacy; Treatment Out | 2004 |
Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Diagnostic and Statis | 2004 |
A cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Drug Hypersensitivity; Female; Humans; Isoxazoles; St | 2004 |
Zonisamide-induced mania in an essential tremor patient.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Essential Tremor; Female; Humans; Isoxazoles; Zonisamide | 2006 |
Zonisamide-induced mania.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Epilepsy, Post-Traumatic | 1990 |